Iran Diabetes Care Drugs And Devices Market Size and Share
Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Growth Rate | 4.18 % |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Iran Diabetes Care Drugs And Devices Market Analysis by Mordor Intelligence
The Iran Diabetes Care Drugs and Devices Market size is expected to register a CAGR of greater than 4.18% during the forecast period.
Inadequate precautions that disrupt traditional patient relationships, drug shortages, disruptions to routine diabetes care, and the lack of infrastructure for telemedicine services increase the risk to developing countries during the COVID-19 pandemic. This presents the most significant challenge in diabetes care management. Diabetes is becoming increasingly common in Iran, as in many other countries. In addition to the difficulties posed by diabetes management in a poor country, Iran has faced new challenges over the past two years due to increased sanctions. During the COVID-19 crisis, the severity of sanctions in Iran more than tripled. Regular blood glucose monitoring, healthy diet, regular physical activity, medication, and adherence to foot care should be considered to control hyperglycemia better and prevent or at least delay complications in people with diabetes. This is an essential component of diabetes self-management. During the COVID-19 crisis, shortages and rising prices of devices such as insulin pens increased patient anxiety and hindered disease management.
One of the most common problems faced by patients is poor medication adherence. Many patients find it challenging to follow recommended treatments. Adherence rates for oral hypoglycemic agents (OHAs) range from 36% to 93% in managing type 1 and type 2 diabetes. Sulfonylureas are commonly used to treat type 2 diabetes. Patient compliance is critical to the effectiveness of oral diabetes therapy. It was crucial to highlight the current state of compliance with diabetes medications among patients with type 2 diabetes in Tehran and the cultural differences within the same Iranian community.
Based on the abovementioned period, the market under study is expected to grow during the analysis period.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Iran Diabetes Care Drugs And Devices Market Trends and Insights
The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
Continuous glucose monitoring sensors use glucose oxidase to measure blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with platinum in the sensor to send an electrical signal to a transmitter. The sensor is the most important part of any continuous blood glucose monitoring device. Technological advances in improving sensor accuracy are expected to drive the growth of the segment during the forecast period.
According to a research study conducted by Joost van der Linden et al. and published in the Diabetes Technology & Therapeutics Journal, real-time continuous glucose monitoring (rtCGM) was employed at a population level to analyze changes in glycemic control with diversified temporal and geographic precision. Furthermore, current continuous glucose monitoring devices can provide a retrospective view of blood glucose levels by downloading the data or giving an up-to-date overview via a receiver display. As newer technologies like cell phone integration become more accessible and cost-effective, this segment is likely to experience growth in the foreseeable future.
The industry players are adopting diverse techniques such as collaborations, partnerships, mergers, acquisitions, and expansions to boost industry disclosure. For instance, WaveForm Technologies Inc., developer of innovative cosmetics for continual glucose monitoring, and A. Menarini Diagnostics S. r. l. guiding diagnostics company, entered a partnership to commercialize WaveForm Technologies' continual Glucose supervise (CGM). Thus, owing to the influences mentioned above, it's expected to control the slice development over the forecast period.
Rising diabetes prevalence
Patients with type 1 diabetes (T1D) must maintain a good lifestyle, influenced by individual personality traits, social interactions, socioeconomic status, and living environment variables. Continuous glucose monitoring (CGM) combined with multiple daily injections (MDI) has been shown to reduce non-severe and severe hypoglycemia in patients with type 1 diabetes who are prone to this side effect. Patients with type 1 diabetes, who are at high risk of hypoglycemia, can use self-contained continuous blood glucose monitoring to control their blood sugar levels, even in the dire living conditions created by the severe lockdowns caused by the COVID-19 pandemic crisis. You can control it. People with diabetes in Iran face economic hardships. Pharmacies do not sell enough insulin for diabetics. Instead, more expensive insulin will be sold on the open market. Parents of diabetic children may not be able to find insulin. For children and adults with type 1 diabetes, insulin costs 20-30% of their monthly family income. This does not include the cost of costly test strips and other consumables. In addition, Iranian insurers are cutting funding for diabetes treatment. Limited insulin is available, and Iranian families with diabetic children are coping by reducing the amount of carbohydrates in their children's diets. People living with Diabetes in Iran confront financial difficulties.
Pharmacies do not sell enough insulin to people with diabetes; instead, insulin is sold on the open market at a higher price. Sometimes, a diabetic child's parent is unable to locate insulin. Insulin costs 20-30% of a family's monthly income for type 1 diabetic children and adults. This does not include the excessively high cost of test strips and other supplies. In addition, insurance firms in Iran are lowering financial assistance for diabetes treatments. Because insulin is scarce, Iranian families with diabetes children adapt by limiting the number of carbs in their children's diet. Though food and lifestyle are highly helpful in managing blood glucose levels, they frequently fail and necessitate oral medication therapy. If the second phase of pharmacological therapy fails, multiple oral medicines will be used. Various therapies will be optimized, and they will be shifted to oral-injectable multiple treatments in the ultimate stages. Guidelines for regulating blood glucose levels have evolved with broad modifications in hyperglycaemia prescription therapy. Considering these developments in diabetes care, the trend in glucose-lowering medicines and their efficacy in blood glucose is critical.
The increasing diabetes prevalence and the above factors will likely drive segment growth over the forecast period.
Competitive Landscape
Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist in enabling insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products.
Iran Diabetes Care Drugs And Devices Industry Leaders
Medtronics
Roche
NovoNordisk
Sanofi
Omnipod
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Iran has clear headroom to expand access to diabetes therapy and monitoring tools, but affordability and supply constraints remain central. For type 1 diabetes patients, insulin can account for 20-30% of monthly family income, excluding test strips and other consumables. A policy-led direction in Iran has included national goals framed around expanding the national diabetes register and broad insurance coverage for basic diabetes medicines and instruments by 2025, which helps set up demand in reimbursable drug classes and core consumables (test strips, pen needles, cartridges, and SMBG supplies) where financing and distribution align.
On the devices side, adoption opportunities cluster in specialist endocrinology and diabetes centers where more intensive insulin management is used, which supports uptake of CGM and, in selected settings, programmable pumps and automated insulin delivery features (for example, carbohydrate ratio calculators and data-driven insulin titration). The market also shows operational whitespace in resilience-oriented offerings, including multi-sourcing of insulin and consumables, distributor-led models for multinational portfolios (such as those associated with Sanofi and Roche), and localized or regionally buffered supply approaches that reduce exposure to sanctions-driven import friction and pricing volatility.
Recent Industry Developments
- July 2026: The General Iranian Pharmaceutical Market notes insulin price volatility with surges over 200% vs pre-Persian New Year, indicating affordability pressure for patients. The development increases incentives to diversify suppliers and pursue cheaper generics and local production.
- April 2026: The Iranian pharmaceutical sector faces removal of subsidized exchange rates for raw material imports, driving significant pricing volatility in medicines. The shift is pushing firms toward localization and supplier diversification to reduce import-cost exposure.
- March 2026: Novo Nordisk faces security risks to Tehran offices and Karaj insulin factory after regional airstrikes, creating uncertainty over local operations. This raises supply risk and shifts focus toward distribution partnerships and localized manufacturing considerations.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers spending in Iran on diabetes care drugs and diabetes care devices used to manage blood glucose and deliver or monitor therapy, measured in USD for value (with unit volumes used as supporting checks).
Scope exclusions: Non-diabetes endocrine drugs, general hospital consumables not used for diabetes care, and broader lifestyle programs are not counted unless they directly map to diabetes drug or device revenue.
Segmentation Overview
- Devices
- Monitoring Devices
- Self-monitoring Blood Glucose Devices
- Continuous Blood Glucose Monitoring
- Management Devices
- Insulin Pump
- Insulin Syringes
- Insulin Cartridges
- Disposable Pens
- Monitoring Devices
- Drugs
- Oral Anti-Diabetes Drugs
- Insulin Drugs
- Combination Drugs
- Non-Insulin Injectable Drugs
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to set the boundaries and build an initial set of demand and supply signals that could be checked against each other. We relied on public health and epidemiology references such as the WHO, the International Diabetes Federation (IDF) diabetes atlas, and Iran health ministry and regulator publications where available, to understand patient loads, diagnosis trends, and therapy patterns.
To connect demand to value, we reviewed import and trade series and product classification notes using sources such as UN Comtrade and World Bank WITS, then cross-checked with peer reviewed studies on antidiabetic medicine utilization and pricing in Iran. We also used company filings, investor presentations, reputable press, and paid subscriptions for company financials and intelligence, plus patent lookups and shipment-level trade checks when needed. This list is illustrative rather than exhaustive, and many other sources were reviewed for data collection, validation, and clarification.
Primary Interviews and Surveys
We consult medicine distributors, device suppliers, endocrinology specialists, pharmacy and procurement professionals, and insurance stakeholders active in Iran. Their input helps clarify local production, reimbursement, stock availability, adoption, and price changes alongside the secondary data. Differences between responses are compared before assumptions are carried into the market model.
Distribution of primary research fieldwork respondents
| Company type | Respondent position |
|---|---|
| Top tier: 25% | CXOs: 15% |
| Mid tier: 55% | Functional/Unit leaders: 30% |
| Smaller Players: 20% | Managers: 55% |
Market-Sizing & Forecasting
The market was sized using a top-down approach where the treated diabetes population and therapy split were translated into annual volumes, then valued using realistic price bands by drug class and device type. To keep the model grounded, results were corroborated with selective bottom-up approximations, such as sampled brand and pack level price checks, channel checks across hospital tenders and retail, and distributor-level sanity checks on unit throughput.
Key inputs included diabetes prevalence and the diagnosed share, insulin versus non-insulin treatment mix, average daily dose and pack utilization for key drug classes, monitoring frequency for SMBG strips and lancets, and the adoption rate of CGM and insulin delivery formats (pens, syringes, pumps). Because local currency and procurement practices can change the realized USD value, conversion timing and typical discounting were discussed with local experts and applied consistently.
Forecasting used scenario analysis supported by trend extrapolation, with the key drivers updated year by year based on what interviewees expect for diagnosis rates, therapy intensification, device uptake, and reimbursement or procurement shifts. Where bottom-up signals were incomplete, gaps were handled by using conservative penetration ranges, then re-checking the implied per-patient annual spend against interview feedback.
Data Validation & Update Cycle
Outputs were validated through multiple checks, starting with internal consistency tests that compare implied per-patient spending, unit volumes, and pricing progression across years. Variances were reviewed against independent signals such as trade values for relevant categories, published medicine utilization studies, and observed device adoption patterns reported by clinicians and channel participants.
Before sign-off, the model and assumptions went through multi-step analyst reviews, and respondents were re-contacted when a major gap or unexpected swing appeared in pricing, volumes, or therapy mix. Reports are refreshed annually, with interim updates when material events occur, and a final pre-delivery pass completed so clients receive the most current view.
Mordor Intelligence's Iran Diabetes Care Drugs and Devices Market Sizing Compared With Other Published Estimates
Published market sizes for diabetes care in Iran can differ across sources, even when they cover the same broad topic. The gap usually comes from what is counted as diabetes care, how prices are converted into USD, and whether the device side covers only monitoring and insulin delivery or includes broader consumables.
The benchmark table shows a noticeable spread in reported USD values, and in Mordor Intelligence's model the scope is limited to diabetes drugs plus defined monitoring and management devices (including SMBG and CGM, and insulin delivery formats), rather than folding in wider hospital supplies or non-diabetes endocrine therapies. Differences also come from whether estimates use a single point exchange rate versus an average period rate, and whether they assume aggressive CGM uptake or keep adoption tied to observed access and clinician feedback.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 1.08 B (2024) | |
| Industry Association A | USD 0.92 B (2024) | Often emphasizes reimbursed and formally procured products, which can undercount out-of-pocket retail volumes for SMBG supplies and selected oral therapies when channel data is fragmented. |
| Trade Journal B | USD 1.25 B (2024) | May include adjacent endocrine and general consumables, and may apply optimistic device penetration and price uplifts without cross-checking implied per-patient spend against treatment intensity and monitoring frequency. |
Looking across the three figures, the main driver of the spread is what gets bundled into the definition of diabetes care and how device adoption is treated in the value build. Our approach keeps the steps traceable, starting from treated patients and usage rates, then stress-testing prices and unit volumes through channel feedback. This helps buyers work with a figure that can be explained and refreshed when conditions change.
Key Questions Answered in the Report
What is the current undefined size?
The undefined is projected to register a CAGR of 4.18% during the forecast period (2026-2031)
Who are the key players in undefined?
Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the undefined.
What years does this undefined cover?
The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the undefined size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
